NY Times Does it Again – Drug Advertisers Get Front Page Coverage to Boost SSRI Market Wed, 2 Jun 2004 The New York Times saw fit to print a report about preliminary, unpublished findings of a study whose authors claim to have “found that Prozac helps teenagers overcome depression far…
When Doctors Go to Class, Industry Often Foots the Bill – WSJ Fri, 6 Dec 2002 A front page article in The Wall Street Journal by Scott Hensley sheds further light on the corruption of medical ethics by focusing on a drug marketing ploy that is promoted as “continuing medical…
FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle Mon, 29 Nov 2004 The Food and Drug Administration is the epicenter of a collision between medical officers in the drug safety office and senior officials in managerial positions whose focus is on facilitating new drug approvals. Officials at the…
“The scariest thing is that nobody knows” risks of depression drugs for children Mon, 10 May 2004 Forest Laboratories, manufacturer of the antidepressant, Celexa / Lexapro, is the latest manufacturer to issue warnings (April 2004) about the possibility that “patients with major depressive disorder, both adult and pediatric, may experience…
Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options Tue, 16 Aug 2005 A series of current articles in The Wall Street Journal, the Journal of the American Medical Association (JAMA), and the New York Times describe the many questionable non-medical income-producing activities that America¹s physicians…
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a…
Follow the Money / Can the Institute of Medicine Review the FDA? Wed, 6 Apr 2005 A letter to the editor published in Nature Medicine by Dr. Bernard Carroll, a past chairman of the FDA Advisory Committee for Psychotropic Drugs, and past chairman of the Department of Psychiatry at Duke…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
“Drug Companies Should Make Their Studies Public” NYT Wed, 13 Aug 2003 Concealed and inaccessible research findings are undermining the integrity of medicine, the advancement of scientific knowledge, and most importantly, secrecy is putting people’s lives in jeopardy because prescribing doctors are ignorant about adverse – even lethal – drug…
Bad Medicine – Editorial – Guardian UK Sat, 12 Jun 2004 New York State Attorney General, Eliot Spitzer, is being recognized as a hero on both sides of the Atlantic. That’s because, unlike FDA officials, he knows how to use a “smoking gun” to affect change in corporate practices to…
Antidepressant Use in Children Soars Despite Efficacy Doubts – Washington Post Mon, 19 Apr 2004 A front page article by Shankar Vedantam in The Washington Post examines the soaring increase in the antidepressant drug prescriptions for children, noting: “The explosion in antidepressant use occurred even though the vast majority of…
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx…
